Oxidative Stress in Cyclosporine-Induced Hypertension: Evidence of Beneficial Effects or Tolerance Development With Nitrate Therapy

Transplantation Proceedings

Volumn 39, Issue 8, 2007, Pages 2494-2500

  Reis, F ^a   Rocha Pereira, P ^b,e   Teixeira de Lemos, E ^a   Parada, B ^a,c   Baptista, S ^a   Figueiredo, A ^c   Santos Silva, A ^d,e   Costa Almeida, C ^a   Mota, A ^c   Teixeira, F ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALPHA TOCOPHEROL; ASCORBIC ACID; CYCLIC GMP; CYCLOSPORIN A; GLUTATHIONE PEROXIDASE; ISOSORBIDE 5 NITRATE; MALONALDEHYDE; MONOPRONT; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; RETINOL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG TOLERANCE; ENZYME ACTIVITY; HYPERTENSION; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; CYCLOSPORINE; HYPERTENSION; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; ISOSORBIDE DINITRATE; MALE; NITRIC OXIDE DONORS; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 35348866153     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.07.030     Document Type: Article

References (34)

1. Taler S.J., Textor S.C., Canzanello V.J., et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 20 (1999) 437
2. Olyaei A.J., de Mattos A.M., and Bennett W.M. A practical guide to the management of hypertension in renal transplant recipients. Drugs 58 (1999) 1011
3. Martinez-Castelao A., Hueso M., Sanz V., et al. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl 68 (1998) 130
4. del Castillo D., Campistol J.M., Guirado L., et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 68 (1998) 135
5. Cartier R., Dagenais F., Hollmann C., et al. Chronic exposure to cyclosporine affects endothelial and smooth muscle reactivity in the rat aorta. Ann Thorac Surg 58 (1994) 789
6. Rego A., Vargas R., Wroblewska B., et al. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J Pharmacol Exp Ther 252 (1990) 165
7. Santiago M., Reis F., Almeida L., et al. Impairment of vascular and platelet nitric oxide and 3′,5′ cyclic guanosine monophosphate content in cyclosporin A-induced hypertensive rats. Fund Clin Pharmacol 17 (2003) 43
8. Oriji G.K., and Keiser H.R. Role of nitric oxide in cyclosporin A-induced hypertension. Hypertension 32 (1998) 849
9. Beckman J. The ABC's of the reactions between nitric oxide, superoxide, peroxynitrite and superoxide dismutase. Oxygen 99-Sunrise Free Radical School 1 (1999)
10. Beutler T.M., Cottet-Maire F., Krauskopf A., et al. Does cyclosporin A generate free radicals?. TiPS 21 (2000) 288
11. Nishiyama A., Kobori H., Fukui T., et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 42 (2003) 754
12. Zalba G., Beaumont F.J., San Jose G., et al. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. Nephrol Dial Transplant 16 suppl 1 (2001) 2
13. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248
14. Miller N.J., Rice-Evans C., Davies M.J., et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 84 (1993) 407
15. Bierig J.G., Tolliver T.J., and Catignani G.L. Simultaneous determination of alpha-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. Ann J Clin Nutr 32 (1979) 2143
16. Saldeen T., Li D., and Mehta J.L. Differential effects of α- and γ-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 34 (1999) 1208
17. O'Neil G.S., Chester A.H., Kushwaha S., et al. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br Heart J 66 (1991) 212
18. Stroes E.S., Luscher T.F., Groot F.G., et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 29 (1997) 570
19. Reis F., Santiago M., Almeida L., et al. Isosorbide-5-mononitrate and L-arginine effect on the cyclosporin-induced arterial hypertension and vascular nitric oxide impairment. In: Tooke J., Shore A., and Whatmore J. (Eds). The Microcirculation and Vascular Biology (2002), Monduzzi Editore S.p.A, Bologna, Italy 257
20. Reis F., Almeida L., Alcobia T., et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3′,5′-monophosphate disturbances. Thromb Res 110 (2003) 107
21. Reis F., Ponte L., Rocha L., et al. Curative isosorbide-5-mononitrate treatment, in opposition to the beneficial preventive one, aggravates the prothrombotic and proconstrictor state in cyclosporine-induced hypertensive rats. Clin Exp Pharmacol Physiol 32 (2005) 640
22. Horowitz J.D. Tolerance induction during therapy with long-acting nitrates: how extensive is the "collateral damage"?. Cardiovasc Drug Ther 18 (2004) 11
23. Csont T., and Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105 (2005) 57
24. Bartholomeusz B., Hardy K.J., and Philips P.A. Modulation of nitric oxide improves cyclosporin A-induced hypertension in rats and primates. J Hum Hypertens 12 (1998) 839
25. Lassila M., Santisteban J., Finckenberg P., et al. Vascular changes in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. J Physiol Pharmacol 52 (2001) 21
26. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?. Am J Physiol Heart Circ Physiol 281 (2001) 981
27. Stroes E.S., Hijmering M., Zandvoort M., et al. Origin of superoxide production by nitric oxid synthase. FEBS Lett 438 (1998) 161
28. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al. Superoxide generation by endothelial nitric oxid synthase: the influence of cofactors. Proc Natl Acad Sci USA 95 (2000) 9220
29. de Lorgeril M., Boissonnat P., Salen P., et al. The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients. Transplantation 58 (1994) 193
30. Parra-Cid T., Conejo Garcia J.R., Carballo Alvarez F., et al. Antioxidant nutrients protect against CyA nephrotoxicity. Toxicology 189 (2003) 99
31. Brown A.S., Moro M.A., Masse J.M., et al. Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. Cardiovasc Res 40 (1998) 380
32. Graham A., Hogg N., Kalyanaraman B., et al. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 330 (1993) 181
33. Watanabe H., Kakihama M., Ohtsuka S., et al. Randomized, double-blind, placebo-controlled study of supplemental vitamin C on attenuation of the development of nitrate tolerance. Circulation 97 (1998) 886
34. Schwemmer M., and Bassenge E. New approaches to overcome tolerance to nitrates. Cardiovasc Drug Ther 17 (2003) 159